INTRODUCTION
Even before nitric oxide (NO) was discovered to be the responsible agent, it was known that activated macrophages produced a substance that was cytotoxic to other cells by irreversibly inhibiting their mitochondrial respiration (Granger, 1980 ). In 1994 a radically different effect of NO on mitochondrial respiration was reported (Brown and Cooper, 1994; Cleeter et al.,1994) . Very low (nanomolar) levels of NO caused a completely reversible inhibition of mitochondrial respiration at cytochrome oxidase in competition with oxygen. This raised the exciting possibility that NO is a physiological regulator of mitochondrial respiration (Brown, 1995) . Potential targets involve inhibition of mitochondrial oxidative phosphorylation at the level of cytochrome c oxidase and inhibition of mitochondrial or cytosolic creatine kinase. NO may also govern substrate utilization. Moreover, NO may influence contractility and thus energy demand by cGMP mediated modulation of L--type Ca 2+ -channel activity and cGMP mediated phosphorylation of phospholamban, enhancing SR Ca 2+ -ATPase activity (Brown 1995) .
While the mitochondrial respiratory chain is very sensitive to blockade by nitric oxide (Koivisto et al., 1997) , it is still unclear whether the basal concentration of nitric oxide in the mitochondria vicinity is quantitatively sufficient to exert a tonic control of oxidative phosphorylation and oxygen consumption. In fact, some studies (Bernstein et al., 1996; Decking et al., 1995) showed that blockade of nitric oxide synthase increased myocardial oxygen consumption(<12%), but others did not (Duncker et al., 2000; Xie et al., 1996) , enhancing endothelial nitric oxide formation in the heart in situ also led to conflicting results Crystal and Gurevicius, 1996) . Only when studying isolated myocardial tissue pieces, did elevated endothelial nitric oxide formation consistently decrease myocardial oxygen consumption (Xie et al., 1996; Loke et al., 1999) . These data have been taken to show that endothelial nitric oxide formation exerts a direct effect on the oxygen consumption of the surrounding cardiomyocytes. In order to test this hypothesis, the effects of bradykinin-enhanced nitric oxide formation on myocardial oxygen consumption rate and contractile function were studied in the saline perfused mouse heart. Myocardial nitric oxide levels were also modulated by applying authentic nitric oxide or an inhibiting cardiac nitric oxide synthesis.
MATERIALS AND METHODS

General
A total of 97 C57/BL6 mice, of body mass between 20 and 30 grams, were anesthetized by intraperitoneal injection of urethane (1.5 mg/kg). Heparin was given simultaneously. Hearts with a wet weight of 116 ± 11 mg were rapidly excised, the aorta was cannulated (20-gauge stainless steel, inner diameter 0.6 mm, outer diameter 0.9 mm) and hearts were perfused at a pressure of 100 mmHg in a non-recirculating Langendorff mode with modified Krebs-Henseleit buffer. It contained (in mM): NaCl 116, KCl 4.6, MgSO 4 Small silver electrodes were gently applied to the right atrium and cardiac apex for cardiac pacing. The following parameters were continuously recorded (Powerlab, ADInstruments, Castle Hill, Australia): coronary flow as measured by a transit-time ultrasonic flowmeter (HSE Harvard Apparatus, Germany), coronary perfusion pressure (CPP), left intraventricular pressure (LVP) as assessed by a fluid-filled balloon, heart rate, and coronary venous pO 2 . For reliable pO 2 measurements, a fraction of the coronary venous effluent (0.5 ml*min -1 ) was sucked continuously through a small diameter tube placed in the opening of the pulmonary artery across a Clark type pO 2 electrode (733, Diamond General, USA) by a peristaltic pump (Minipulse 3, Gilson Medical Electronics, France). For the measurement of nitrite release, coronary venous effluent was collected as well.
Protocols
After completion of the preparation, hearts were initially perfused at constant pressure (100 mmHg) inside a water-jacketed chamber set to 37 o C. Cardiac pacing (500 min -1 ) was initiated and continued throughout. All hearts were allowed to equilibrate for 20 minutes before left ventricular end diastolic pressure was set to 5 mmHg.
Twenty minutes after the onset of cardiac pacing, the coronary perfusion rate was fixed to the steady state flow finally attained (in general about 1.5 -2.5 ml*min -1 ) and was maintained constant thereafter by a peristaltic pump. Basal functional parameters were acquired before subjecting the hearts to the different experimental protocols. In the first experiments, bradykinin only was applied (n=17). Since under conditions of constant coronary flow, bradykinin induced a massive decrease in perfusion pressure affecting contractility to a significant extent, in the main set of experiments (n=80), maximal vasodilatation was initiated by application of adenosine (1 mmol*l -1 ) which was continued throughout, before starting the different interventions under steady-state conditions. Bradykinin (10 mmol*l adenosine. At the end of the experiment, hearts were weighed after gentle blotting.
Measurement of myocardial oxygen consumption
To enable the sensitive detection of even small changes in myocardial oxygen consumption, hearts were perfused at a constant arterial pO 2 (600 mmHg) and flow. In brief, measurement of the coronary venous pO 2 (see above) allowed the determination of the arterio-venous pO 2 difference. Since flow was maintained constant, any change in oxygen consumption translated into a considerable change in coronary venous pO 2 . Preliminary experiments demonstrated both the stability of the pO 2 electrode's signal at a given pO 2 (electrode drift less than 0.1 mmHg *min -1 ) as well as the ability of the set-up to respond to changes in myocardial oxygen consumption.
Nitrite release measurements
To obtain a measure of cardiac nitric oxide formation, the nitrite release of the saline perfused hearts was determined. Measurement of nitrate release was not attempted, since it is complicated by a low nitrate content of the arterial inflow medium due to contamination of the commonly available medium constituents. The arterial inflow and coronary venous outflow nitrite concentration was measured by a nitric oxide analyser (NOA, Model 280, Sievers, Boulder, USA) based on the chemiluminescence method. Comparison with nitrite standards enabled quantification, the detection limit being 1 pmol. To measure reliably the low coronary nitrite concentrations, an injection volume of 500 ml was employed. For standards in the range from 1 -200 nmol*l -1 nitrite, a linear correlation coefficient r of 0.98 was obtained.
Chemicals
Bradykinin, N G -monomethyl-L-arginine, and urethane were obtained from Sigma (Deisenhofen, Germany) and heparin was purchased from HoffmannLaRoche (Grenzau, Germany). All other reagents were obtained from Merck (Darmstadt, Germany). Nitric oxide gas was obtained from AGA gas, Hamburg, Germany.
Data analysis
For statistical analysis, two tailed t tests for paired or unpaired data were used as appropriate. A p value less than 0.05 was considered significant. All data are given as means ± SEM.
RESULTS
Effect of increased endothelial nitric oxide-formation on myocardial contractile function and oxygen consumption
To increase the level of endothelium-derived nitric oxide, bradykinin (10 mmol*l -1 ) was applied. The effects of bradykinin on cardiac functions and oxygen consumption were first analyzed in the isolated mouse heart perfused with constant a coronary flow at basal vascular tone (n=17). When bradykinin was applied, a major fall in perfusion pressure was observed in association with a decrease in contractility and myocardial oxygen consumption. This apparent decrease was due to the decrease in perfusion pressure, since adenosine (1 mmol*l 1 , n = 12), an endothelium independent agent, had a quantitatively comparable effect (Table 1 ). It suggests that the effect noticed with bradykinin seems to be primarily caused by vasodilatation.
To avoid the effect of vasodilatation on coronary perfusion pressure, contractility and myocardial oxygen consumption, in the subsequent series of experiments the coronary blood vessels were maximally dilated by previous and continuous infusion of adenosine (1mmol*l -1 ). As a consequence, when adenosine-induced vasodilatation with its concomitant decrease in perfusion pressure, contractility and myocardial oxygen consumption preceded application of bradykinin, bradykinin did not result in any further decrease in contractility and myocardial oxygen consumption (Table 2, Figure 1 ). 
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Koji} Zvezdana The effects of modulation of endothelial derived nitric oxide level on contractile function and myocardial oxygen consumption in saline perfused mouse heart Figure 1 . Original trace -Lack of effect of bradykinin (10 mmol*l -1 ) on contractility (maximal rate of change of left ventricular pressure with time -LV dP/dt max ) and myocardial oxygen consumption (MVO 2 ) in presence of maximal vasodilatation induced by adenosine (1 mmol*l -1 ) (n=12).
Exogenous application of nitric oxide
To gain an insight into the nitric oxide concentration necessary to depress the cardiac contractile function and myocardial oxygen consumption significantly, a concentration-response curve for exogenously applied authentic nitric oxide was obtained, again in the presence of adenosine (1 mmol*l -1 ). As shown in trace 2 (Figure 2) , in the concentration range less than 2 mmol*l -1 , no effect of nitric oxide on either contractile function or myocardial oxygen consumption was noticed (n=9). Only at concentrations higher than 2 mmol*l -1 , nitric oxide impaired the contractile function and decreased myocardial oxygen consumption in a concentration-dependent manner (n=6).
Nitrite release
To assess the rise in nitric oxide induced by bradykinin (10 mmol*l -1 ), exerting a maximal vasodilatory effect, coronary venous nitrite release was determined. The basal coronary venous nitrite concentration was 23 ± 3 nmol*l -1 . Following the correction for the arterial inflow nitrite concentration of 13 nmol*l -1 , basal myocardial nitrite release was determined to be 192 pmol*g -1 *min -1 . Bradykinin induced a 5-fold rise in nitrite release (to 960 pmol*g -1 *min -1 ), the coronary venous effluent concentration being 66 ± 8 nmol*l -1 ( Figure 3 ). 
Decreased level of endogenous endothelial nitric oxide formation after inhibition of nitric oxide synthase
To test whether the basal formation of nitric oxide contributes to a tonic inhibition of myocardial oxygen consumption, endothelial nitric oxide synthesis was blocked by N G -monomethyl-L-arginine (L -NMMA) (100 mmol*l -1 ), again during maximal vasodilatation (adenosine,1mmol*l -1 ). Under these conditions, L-NMMA induced a small rise in coronary perfusion pressure (46.3 ± 1.5 vs. 44.6 ± 1.4 mmHg) and contractility (1.9 ± 0.1vs.1.84 ± 0.07 mmHg*ms -1 ), but had no effect on oxygen consumption. Thus, oxygen consumption was 9.93 ± 2.60 and 9.87 ± 2.70 %, respectively, of arterially supplied oxygen with or without nitric oxide synthase blockade by L-NMMA (n=6).
DISCUSSION
The present study demonstrates that a 5-fold rise in endothelial nitric oxide formation does not act on contractile function and myocardial oxygen consumption in the saline perfused mouse heart when the confounding effects of vasodilatation are carefully controlled. When modulating myocardial nitric oxide levels using arterial application of authentic nitric oxide, concentrations more than 2 mmol*l -1 of nitric oxide were required to induce a decrease in myocardial oxygen consumption. This concentration is high when compared to the basal nitrite release of about 10 nmol*l -1 . Consistent with these data, blockade of nitric oxide synthase by L-NMMA showed no effect on myocardial oxygen consumption. There was thus no direct evidence to support the idea of a tonic control of oxygen consumption by endogenous nitric oxide formation. In fact, very high arterial nitric oxide concentrations were needed to inhibit myocardial oxygen consumption. 
121
Koji} Zvezdana The effects of modulation of endothelial derived nitric oxide level on contractile function and myocardial oxygen consumption in saline perfused mouse heart Figure 3 . Nitrite release (pmol*g -1 *min -1 ) in the coronary venous effluent under basal conditions (Basal) and during application of bradykinin (Bradykinin). Significance mark is ** p<0.01 vs.basal (n=17). Based on these observations, we conclude that endothelial-derived nitric oxide exerts no control on mitochondrial oxygen consumption, most likely due to the rapid degradation of nitric oxide, e.g. by myoglobin.
The main data of the present study appear to be in conflict with the recent observation of a substantial decrease in myocardial oxygen consumption upon bradykinin in cardiac tissue (Xie et al., 1996; Loke et al., 1999; Pittis et al., 2000) . The reason for this discrepancy could be as followed:
-The bradykinin-concentration in the present study is comparable to the concentrations used in these recent observations (Loke et al., 1999; Pittis et al., 2000) . This concentration was more than 10-fold greater than the maximally effective vasodilatory concentration in mice (Flögel et al., 2001) . Thus, an insufficient bradykinin-concentration cannot explain the present lack of effect. -To exclude insufficient nitric oxide formation in the isolated mouse heart, we determined the net nitrite release as a commonly employed index of cardiac nitric oxide formation. Basal nitrite release (10 nmol*l -1 ) was similar to that of guinea pig hearts (Kelm et al., 1997) . The bradykinin-induced rise (4-fold) in nitrite by far exceeded that seen in canine coronary microvessels (Pittis et al., 2000) and in guinea pig hearts (Kelm and Schrader, 1997) . Thus, impaired nitric oxide formation seems to be unlikely.
-Adequate myocardial oxygenation is critical and indicated both by the level of free energy of ATP hydrolysis (63 kJ/mol) (Flögel et al., 1999) and by a high myocardial oxygen consumption (10 mmol*g -1 *min -1 ). In contrast, when myocardial tissue pieces were studied, myocardial oxygen consumption ranged from 0.07 to 0.2mmol*g -1 *min -1 only (Loke et al., 1999; Pittis et al., 2000) , strongly suggesting insufficient oxygenation, at least in the tissue core. We would therefore like to suggest that the discrepancy between bradykinin's effect on myocardial oxygen consumption in isolated hearts and tissue pieces is at least partially explained by differences in pO 2 . It is well known that the inhibitory action of nitric oxide at cytochrome c oxidase is competitive with regards to oxygen (Koivisto et al., 1997) . A low pO 2 will thus facilitate inhibition of oxidative phosphorylation by nitric oxide and result in a high sensitivity of tissue pieces to bradykinin-induced nitric oxide formation. However, this is not the case in the saline perfused heart.
The rate of bioactive nitric oxide formation in the heart in vivo is most likely similar to the saline perfused heart. Tonic nitric oxide formation contributes to the maintenance of vascular tone but it is below the threshold for maximal vasodilatation. In vivo, the presence of hemoglobin presents a further source for nitric oxide degradation and inactivation. In consequence, in the heart in vivo it is not likely that endothelial nitric oxide formation contributes to the control of mitochondrial respiration.
Against this background, it is difficult to understand, why nitric oxide synthase blockade, e.g. in guinea pigs and dogs (Bernstein et al., 1996; Decking et al., 1995) induced a rise in myocardial oxygen consumption. It is possible that nitric oxide, formed within the mitochondria, is responsible for this effect. Mitochondrial nitric oxide formation would enable direct inhibition of the respiratory chain by nitric oxide and bypass the potent inactivation of nitric oxide by myoglobin recently demonstrated by us (Flögel et al., 2001) . It seems to be most likely that this degradation pathway made the application of very high arterial nitric oxide concentrations necessary to induce the contractile dysfunction and decline in myocardial oxygen consumption. In addition, this nitric oxide inactivation makes tonic control of mitochondrial oxidative phosphorylation by endothelium-derived nitric oxide hardly possible.
